FDA 483 - Yaopharma Co Ltd - March 29, 2019

An FDA inspection of Yaopharma Co Ltd in Chongqing, China, revealed a significant issue with data integrity and adherence to written procedures. Specifically, an analyst failed to follow standard operating procedures for recording data, leading to discrepancies in laboratory notebooks and investigation results. This indicates a breakdown in quality control and reliable record-keeping practices.